The TRIPLEX study: use of patient-derived tumor organoids as an innovative tool for precision medicine in triple-negative breast cancer

The TRIPLEX study: use of patient-derived tumor organoids as an innovative tool for precision medicine in triple-negative breast cancer

Abstract Background Triple negative breast cancers (TNBC) account for approximately 15% of all breast cancers and are associated with a shorter median survival mainly due to locally advanced tumor and high risk of metastasis. The current neoadjuvant treatment for TNBC consists of a regimen of immune...

Full description

Bibliographic Details
Main Authors: Jordane Divoux, Romane Florent, Margaux Jacobs, Justine Lequesne, Jean-Michel Grellard, Chankannira San, Sara Grossi, Katia Kerdja, Bénédicte Clarisse, Gwenaelle Boudier, François Cherifi, Mélanie Briand, Enora Dolivet, Alisson Johnson, Brice Dubois, Valentin Harter, Joëlle Lacroix, Charlotte Raboutet, Brigitte Marie, Nathalie Rousseau, Cécile Blanc-Fournier, Dominique Vaur, Martin Figeac, Laurent Poulain, Louis-Bastien Weiswald, George Emile
Format: Article
Language:English
Published: BMC 2023-09-01
Series:BMC Cancer
Subjects:
Triple negative breast cancer
Patient-derived tumor organoids
Predictive functional assays
Chemo-immunotherapy
Online Access:https://doi.org/10.1186/s12885-023-11362-8

Similar Items

Similar Items